GRObio's mission is to transform protein-based therapies for increasingly prevalent chronic medical conditions including autoimmune and metabolic diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/06/21 | $25,000,000 | Series A |
Digitalis Ventures Innovation Endeavors Leaps by Bayer  Redmile Group | undisclosed |
| 08/04/24 | $60,000,000 | Series B |
Access Biotechnology Atlas Venture Digitalis Ventures Innovation Endeavors Leaps by Bayer Redmile Group | undisclosed |
